BiomX
NESS ZIONA, Israel · Biotechnology, Healthcare, Health Care
BiomX is focused on acquiring and developing technologies that identify, analyze, protect against, and support faster responses to physical threats. The company operates as a subsidiary of BiomX Inc. and is involved in enhancing security systems. With a strategic focus on defense and security, BiomX aims to integrate advanced technologies into operational environments. It addresses critical infras
Key facts
- Headquarters
- NESS ZIONA, Israel
- Employees
- 20
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (HLSQ)
- Website
- biomx.com
- Company page
Recent activity at BiomX
- : SEC 8-K (7.01): Tessera Defense and Homeland Security Inc. has reported updated revenue targets for 2027 and long-term goals for 2028-2029. This disclosure indicates management's current expectations are predicated on sustained market demand for their technologies, successful customer project execution, and growth initiatives. The report highlights anticipated strategies for converting identified commercial opportunities into secured business and expanding existing customer relationships. The event took place on September 29, 2026, aligning with the company's business outlook and strategic planning processes.
- : SEC 8-K (1.01): On September 24, 2026, Tessera Defense and Homeland Security Israel Ltd., a wholly owned subsidiary of Tessera Defense and Homeland Security Inc., entered into a Material Definitive Agreement with X S.E. Security and Defense Ltd. for the purchase of 51% of the shares of RT LTA Systems Ltd. The Option Agreement allows Tessera to purchase all shares held by X SE, representing a significant stake in RT, which specializes in tethered aerostat systems for surveillance and communications. This strategic acquisition could enhance Tessera's capabilities in defense technology, particularly in airborne surveillance systems.
- : SEC 8-K (5.07): On August 25, 2026, BiomX Inc. held a Special Meeting of Stockholders where critical matters were voted on. With a record date of August 10, 2026, 9,813,430 shares, constituting approximately 36.9% of the outstanding shares, were represented at the meeting. The meeting's intent was primarily to secure approval for the Issuance Proposal, aligning with Sections 712 and related provisions. The voting results reflect stockholder engagement and the importance of the proposals discussed, which may have strategic implications for the company’s financing and operational future.
- : BiomX to acquire 60% of Tsoock for $10.4 million
- : BiomX acquires Zorronet for defense tech expansion
- : SEC 8-K (5.07): On March 11, 2026, BiomX Inc. held a special meeting of stockholders, which was originally scheduled for February 25, 2026, but was adjourned to allow additional time for stockholder votes. As of the record date, February 3, 2026, there were 1,593,516 shares of common stock outstanding, all of which were eligible to vote at the meeting. The special meeting achieved quorum with all shares present either in person or by proxy, and no broker non-votes were recorded. The outcome of the proposals will impact the governance of the company and strategic decision-making moving forward.
- : BiomX Appoints Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer
- : BiomX
- : BiomX Announces Financing of $12 Million to Advance BX004 Program in Cystic Fibrosis Patients
- : BiomX
BiomX funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2026 | Venture | $3.3M |
| Apr 2024 | Venture | $61.5M |
| Mar 2023 | Seed | $1.5M |
| Jan 2022 | Seed | $3.0M |
| Oct 2021 | Venture | $3.0M |
Leadership
- Roy Opperman, Director of Intellectual Property
- Jonathan Solomon, Executive Officer, Director
- Gbola Amusa, Director
- Russell Greig, Director
- Jonas Grossman, Director
- Alan Moses, Director
- Paul Sekhri, Director
- Jonathan Solomon, Executive Officer, Director
- Lynne Sullivan, Director
- David Rokach, Chief Financial Officer
- Michael Oster, Chief Executive Officer
- Lynne Sullivan, Director
Verified email and direct lines for BiomX’s decision-makers are on Fundz. See plans
Employee benefit plans
BiomX files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
BiomX in the news
- BiomX: Zorronet Completes Transition to New Advanced Data Center Supporting Business Expansion and Enhanced AI Capabilities - Yahoo Finance (Jul 10, 2026)
- PHGE Stock Jumps As BiomX Launches AI Command App - StocksToTrade (May 26, 2026)
- BiomX: Subsidiary Zorronet Commences Installation and Operation of AI-Powered Detection Systems Under Israel Railways Agreement - Yahoo Finance (Jul 06, 2026)
- BiomX Subsidiary Zorronet Begins AI and ML Detection System Installation on Israel Railways Network - Moomoo (Jul 06, 2026)
- Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections - Frontiers (Dec 18, 2025)
- Safety concerns halt BX004 phage therapy trial for CF infection - Cystic Fibrosis News Today (Dec 09, 2025)
- BiomX Signs Non-Binding Letter of Intent to Acquire Control of Revenue-Generating Security Infrastructure and Systems Integration Company, Expanding Its Security Platform with Critical Infrastructure and Secure-Site Integration Capabilities - Yahoo Finance (Jul 08, 2026)
- BiomX Announces Entry into Merger Agreement with Adaptive - globenewswire.com (Mar 06, 2024)
Companies similar to BiomX
- Oncotelic Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Galecto · Biotechnology, Healthcare, Health Care, Therapeutics
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
- Ovid Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About BiomX: questions and answers
What does BiomX do?
BiomX is focused on acquiring and developing technologies that identify, analyze, protect against, and support faster responses to physical threats. The company operates as a subsidiary of BiomX Inc. and is involved in enhancing security systems. With a strategic focus on defense and security, BiomX aims to integrate advanced technologies into operational environments. It addresses critical infras
Where is BiomX headquartered?
BiomX is headquartered in NESS ZIONA, Israel.
How many employees does BiomX have?
BiomX has about 20 employees.
Has BiomX raised funding?
Yes. Fundz has recorded 5 funding events for BiomX. The most recent, $3.3M, was in Jan 2026.
Who leads BiomX?
Michael Oster is a Chief Executive Officer at BiomX.
What is the latest news on BiomX?
On Sep 29, 2026, SEC 8-K (7.01): Tessera Defense and Homeland Security Inc. has reported updated revenue targets for 2027 and long-term goals for 2028-2029. This disclosure indicates management's current expectations are predicated on sustained market demand for their technologies, successful customer project execut
Is BiomX a public company?
Yes. BiomX is publicly traded under the ticker HLSQ.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy